

United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS (C) Washington, D.C. 20231

CONFIRMATION NO. ATTORNEY DOCKET NO. FIRST NAMED INVENTOR APPLICATION NO. FILING DATE 2634 Yukiko Sasaki 11/13/2000 09/700,187

> 7590 01/29/2003

赛 275352 是於是是 Cushman Darby & Cushman.

Pillsbury Madison & Sutro
Ninth Floor
1100 New York Avenue NW
Washington, DC 20005-3918

DATE MAILED: 01/29/20...

Please find below and/or attached an Office communication concerning this application or proceeding. PAPER NUMBER

The state of the spirit 京都 不通

7

DENFACE-1994

SERIAL NUMBER FILING DATE

FIRST NAMED APPLICANT

ATTORNEY DOCKET NO.

09/700,187

DR. GEOF	MINER RGIA HELMER
ART UNIT	PAPER NUMBER
1638	. 10
DATE MAILED:	· · · · · · · · · · · · · · · · · · ·

Please find below a communication from the EXAMINER in charge of this application

Commissioner of Patents

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

Applicant is given ONE MONTH, or THIRTY DAYS, whichever is longer, from the mailing date of this letter within which to comply with the sequence rules, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a). In no case may an applicant extend the period for reply beyond the SIX MONTH statutory period. Direct the reply to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the reply.

Any inquiry concerning this communication should be directed to at telephone number (703)30% - 407%

DR. GEORGIA HEI MED

PHUONG T. BUI

PRIMARY EXAMINER

Application No.09	1200	18	1
-------------------	------	----	---

NOTICE TO COMPLY WITH EQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s):
1. This application clearly fails to comply with the requirements of 37 CFR 1.821 - 1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).
3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached marked-up copy of the "Raw Sequence Listing."
5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).
Applicant must provide: need to be over to all primare and the An Initial or substitute computer reagable form (CRF) copy of the "Sequence Listing" The whole it is the sequence Listing to the sequence Listing the sequence Listing the sequence to the sequence Listing the sequence
An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d)
For questions regarding compliance with these requirements, please contact:
For Rules Interpretation, call (703) 308-1123 For CRF submission help, call (703) 308-4212 For Patentln software help, call (703) 308-6856
For Harrie the primer of p. 30 of the Beafication have no SID#5.